RET fusion gene: translation to personalized lung cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Lung adenocarcinoma (LADC) development is frequently driven by oncogenes like KRAS, EGFR, and ALK.
• Targeted therapies against EGFR mutations and ALK fusions have shown efficacy in LADC.
• The RET fusion gene has recently emerged as a novel targetable driver in LADC.

Purpose of the Study:

• To highlight the identification of RET fusion genes as a new targetable driver in LADC.
• To discuss the therapeutic potential of RET tyrosine kinase inhibitors in LADC.

Main Methods:

• Literature review and analysis of existing research on LADC driver oncogenes.
• Examination of in vitro and in vivo data for RET inhibitors.
• Review of ongoing clinical trials for RET fusion-positive non-small-cell lung cancer.

Main Results:

• RET fusions are identified in 1-2% of LADC cases.
• Existing FDA-approved RET tyrosine kinase inhibitors demonstrate promising therapeutic effects.
• Early patient data and ongoing clinical trials suggest efficacy of RET inhibitors.

Conclusions:

• RET fusion represents a significant and targetable driver in a subset of LADC.
• RET tyrosine kinase inhibitors offer a promising therapeutic avenue for patients with RET fusion-positive LADC.
• Further clinical investigation is warranted to establish the full therapeutic benefit of RET inhibitors in LADC.